JAC Advance Access originally published online on June 9, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy 2004 54(1):21-28; doi:10.1093/jac/dkh309
JAC vol.54 no.1 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.
Review |
Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis
1 Laboratory of Experimental Internal Medicine and 2 Department of Intensive Care Medicine, C3-329, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
* Tel: +31-20-5669111; Fax: +31-20-5669568; Email: m.j.schultz{at}amc.uva.nl
Diffuse panbronchiolitis (DPB) is a pulmonary disease characterized by chronic inflammation of the bronchioles and chronic infiltration of inflammatory cells in the lungs. DPB has several features in common with cystic fibrosis (CF). Clinical trials in patients with DPB or CF suggest a potential role for maintenance (long-term and low-dose) macrolide therapy in the treatment of these chronic pulmonary conditions. Indeed, these studies demonstrate improved clinical and physiological states with macrolide therapy. The beneficial effects of long-term low-dose macrolides are not related to their antimicrobial properties, since levels of macrolides with low-dose treatment are too low to have sufficient antimicrobial effects. Data indicate that macrolides may have immunomodulatory activities: (1) in vitro and ex vivo studies clearly show that macrolides can influence cytokine production by several cell types; (2) furthermore, macrolides can alter polymorphonuclear cell functions in vitro and ex vivo. Although immunomodulation may serve as one explanation for the beneficial effects of macrolides in patients with chronic pulmonary inflammation, the effect of low-dose macrolide therapy on biofilm-formation may form a second explanation for the positive effects of long-term low-dose macrolide therapy. In the present paper, the clinical trials on maintenance macrolide therapy in patients with DPB or CF are reviewed. This is followed by a discussion on the immunomodulating effects of macrolides, and the effects of macrolides on biofilm formation.
Keywords: erythromycin , azithromycin , clarithromycin , innate immunity , alveolar macrophages , polymorphonuclear cells , cytokines , biofilms
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. I. Restrepo, E. M. Mortensen, G. W. Waterer, R. G. Wunderink, J. J. Coalson, and A. Anzueto Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Eur. Respir. J., January 1, 2009; 33(1): 153 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Diaz, E. M. Mortensen, A. Anzueto, and M. I. Restrepo Review: Novel targets in the management of pneumonia Therapeutic Advances in Respiratory Disease, December 1, 2008; 2(6): 387 - 400. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Isozumi, Y. Ito, T. Ishida, M. Osawa, T. Hirai, I. Ito, K. Maniwa, M. Hayashi, H. Kagioka, M. Hirabayashi, et al. Genotypes and Related Factors Reflecting Macrolide Resistance in Pneumococcal Pneumonia Infections in Japan J. Clin. Microbiol., May 1, 2007; 45(5): 1440 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. V. Hawkyard and R. J. Koerner The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks J. Antimicrob. Chemother., March 1, 2007; 59(3): 347 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Blau, K. Klein, I. Shalit, D. Halperin, and I. Fabian Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-{kappa}B activation in a cystic fibrosis epithelial cell line Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L343 - L352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Asgrimsson, T. Gudjonsson, G. H. Gudmundsson, and O. Baldursson Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1805 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Giamarellos-Bourboulis, V. Tziortzioti, P. Koutoukas, F. Baziaka, M. Raftogiannis, A. Antonopoulou, T. Adamis, L. Sabracos, and H. Giamarellou Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae J. Antimicrob. Chemother., May 1, 2006; 57(5): 937 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. F. Little Treating Acute Asthma with Antibiotics -- Not Quite Yet N. Engl. J. Med., April 13, 2006; 354(15): 1632 - 1634. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Phaff, H. A. W. M. Tiddens, H. A. Verbrugh, and A. Ott Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis J. Antimicrob. Chemother., April 1, 2006; 57(4): 741 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yasutomi, Y. Ohshima, N. Omata, A. Yamada, H. Iwasaki, Y. Urasaki, and M. Mayumi Erythromycin Differentially Inhibits Lipopolysaccharide- or Poly(I:C)-Induced but Not Peptidoglycan-Induced Activation of Human Monocyte-Derived Dendritic Cells J. Immunol., December 15, 2005; 175(12): 8069 - 8076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Yates, D. M. Murphy, I. A. Forrest, C. Ward, R. M. Rutherford, A. J. Fisher, J. L. Lordan, J. H. Dark, and P. A. Corris Azithromycin Reverses Airflow Obstruction in Established Bronchiolitis Obliterans Syndrome Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 772 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Amsden Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother., January 1, 2005; 55(1): 10 - 21. [Abstract] [Full Text] [PDF]
|
|